NCT07346014 Sleep and Circadian Interventions for College Students at High Risk of Suicide
| NCT ID | NCT07346014 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Sleep Disturbance |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-06-18 |
| Primary Completion | 2029-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2026-06-18 with a primary completion date of 2029-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.
Eligibility Criteria
Inclusion Criteria: * Enrolled or planning to enroll in treatment at COSTAR Intensive Outpatient Program * English language fluency and literacy sufficient to engage in study protocol * Suicidal ideation or suicide attempt in past month * Clinically significant sleep disturbance, operationalized as Pittsburgh Sleep Quality Index global PSQI score \>= 7, and/or delayed bedtimes (\>midnight), and/or \>2 hours in sleep timing variability Exclusion Criteria: * Non-affective psychosis per electronic health record (EHR) review and/or baseline clinical assessment, or symptom severity or psychosocial functioning impairments that preclude participation * Contraindications for either sleep deprivation or bright light therapy (e.g., bipolar disorder; seizure disorder; photosensitizing medication) * Intellectual disability precluding comprehension of study procedures * Evidence of untreated obstructive sleep apnea and/or restless legs syndrome * Life-threatening medical condition requiring immediate treatment (such as cancer; end stage disease) * Pregnancy
Contact & Investigator
Tina Goldstein, PhD
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT07346014 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 25 Years, studying Sleep Disturbance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07346014 currently recruiting?
Yes, NCT07346014 is actively recruiting participants. Contact the research team at ricedm@upmc.edu for enrollment information.
Where is the NCT07346014 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT07346014 clinical trial?
NCT07346014 is sponsored by University of Pittsburgh. The principal investigator is Tina Goldstein, PhD at University of Pittsburgh. The trial plans to enroll 90 participants.